This infographic shows the shifting landscape of HIV R&D. It emphasizes that funding is decreasing and that priorities are changing. This poster was presented in 2014 at the HIV Research for Prevention (R4P) conference in South Africa.
Tracking Investments and Expenditures in HIV Prevention Research and Development: Sustaining Funding in a Shifting International Development Landscape
Innovation in Stakeholder Engagement: Piloting a Monitoring and Evaluation Toolkit
The M&E toolkit was developed to better understand and assess the impact of engagement on clinical trials and communities. The tools and web-based analysis database were piloted in South Africa and Kenya. This poster, presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa, outlines the process and lessons learned.
Resource Tracking to Ensure Accountability and Sustainability: HIV Prevention, Treatment U=U, Diagnostics and Cure Research Investment Analysis
This infographic explains how AVAC tracks HIV expenditures and investments. This has resulted in accurate and consistent year-to-year comparisons of grants and investment figures. This poster was presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa.
HIV Cure Research – An introductory fact sheet
This introductory 2-page document defines cure, reviews the scientific evidence to date, and outlines key research strategies currently being pursued. This fact sheet is part of a series on emerging HIV prevention strategies.
Px Wire July-September 2014, Vol. 7, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue comes out on the eve of the International AIDS Conference in Melbourne, Australia—and we begin with “AVAC’s Take” on key messages and commitments to look for at and after the meeting. We also call for more PrEP demonstration projects and provide an update of the proposed ECHO trial.
Px Wire October-December 2014, Vol. 7, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue, we offer a selective “state of the union” update on various areas of the prevention field—highlighting key developments, messages and areas of work that warrant particular joint attention at the first HIV Research for Prevention (HIV R4P) conference and beyond.
Homophobic legislation and its Impact on Human Security
This report by the MSMGF explores the circumstances around the enactment of new anti-homosexual legislation in Nigeria and Uganda, examining five categories of insecurity faced by lesbian, gay, bisexual and transgender (LGBT) people in the context of these laws.
Data and Uncertainty: Understanding updates on hormonal contraceptives and HIV
AIDS 2014 featured analyses of data on the potential relationship between hormonal contraceptives and risk of HIV infection. Researchers Charles Morrison (FHI 360) and Kristin Wall (Emory University), and Mary Lyn Gaffield from the WHO discussed the newest findings and guidance.
The Research to Rollout Timeline for Pre-Exposure Prophylaxis(PrEP)
There is a complex process for new prevention options to move from evidence of benefit in a clinical trial to being available to the public for use. This infographic traces milestones in recent years along the path from research to rollout of pre-exposure prophylaxis (PrEP). The timeline plots key dates for four major clinical trials and related guidance and regulatory decisions.
Microbicide Clinical Trials Timeline
This graphic from AVAC’s Microbicides by the Numbers one-pager tracks major ongoing and completed microbicide trials. It shows the trials that have provided the current evidence about tenofovir gel as well as planned gel and ring trials.